Vaccines & Vaccination 

Biography

Dr. Tobin has led research and technical programs at BMI since 1999. Dr. Tobin has significant experience in project direction and management; design, planning, and execution of research projects; personnel management; coordination of multi-site studies and development of research facilities. Dr. Tobin fosters a highly interactive research and development group to apply the Company’s proprietary technology, Immune Refocusing Technology, to the design of antigens that induce broader protection against heterologous challenge. Dr. Tobin continues to maintain research projects and interests in the development of broadened vaccines against HIV-1, influenza virus, rhinovirus, malaria, dengue virus, and non-typeable hemophilus influenza. Prior to joining BMI, Dr. Tobin was a Senior Scientist and Group Leader (Gene Expression Regulation Group) for SAIC-Frederick at the National Cancer Institute. While at the NCI, Dr. Tobin led projects related to development of virus-like particle (VLP) based vaccines for HIV-1, optimization of recombinant protein expression, development of animal models for AIDS and cancer, and investigations into the pathobiology and molecular mechanisms of bovine immunodeficiency virus (BIV) and visna virus

Research Interest

development of broadened vaccines against HIV-1, influenza virus, rhinovirus, malaria, dengue virus, and non-typeable hemophilus influenza